UBXN2A

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, UBXN2A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated UBXN2A data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher UBXN2A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UBXN2A expression acts as an unfavorable survival marker.

KIRC and LUAD are the cancer types where UBXN2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
KIRCOSMedianAll0.1330.805<.00142view →
LUADOSMedianAll0.1880.670.0493view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

UBXN2A–KIRC (OS)

Kaplan–Meier survival curve for UBXN2A mutant vs wild-type samples in KIRC.

Open the KIRC breakdown →

Exploration